In clinical practice, a population-based cohort study revealed that type 2 DM patients treated with SGLT2 inhibitor therapy had a lower risk of new-onset arrhythmia and mortality than those of patients treated with non-SGLT2 inhibitor therapy [17]. The gene discussed is SLC5A2; the disease is Arrhythmia.